Serum interleukin-6 is an indicator for severity in 901 patients with SARS-CoV-2 infection: a cohort study - Zhang, Jing; Hao, Yiqun; Ou, Wuling; Ming, Fei; Liang, Gai; Qian, Yu; Cai, Qian; Dong, Shuang; Hu, Sheng; Wang, Weida; Wei, Shaozhong (Journal of translational medicine, 2020)
Keywords: Aged; Antibodies, Monoclonal, Humanized - administration & dosage; Betacoronavirus; Cardiovascular disease; Clinical trials; Cohort analysis; Comorbidity; Coronavirus Infections - blood; Coronavirus Infections - drug therapy; Coronaviruses; COVID-19; COVID-19 Drug Treatment; Cytokines; Diagnosis; Fatalities; Female; Health aspects; Hospitals; Humans; Immunologic tests; Immunosuppressive agents; Infections; Intensive care; Interleukin 6; Interleukin 6 receptors; Interleukin-6 - blood; Kinetics; Laboratories; Male; Medical imaging; Medical prognosis; Middle Aged; Monoclonal antibodies; Oxygen therapy; Pandemics; Patients; Pneumonia, Viral - blood; Pneumonia, Viral - drug therapy; Propensity Score; Retrospective Studies; SARS-CoV-2; Severe acute respiratory syndrome coronavirus 2; Software; Tocilizumab; Treatment Outcome; Ventilators; China; United States--US; COVID-19; SARS-CoV-2; Tocilizumab; Interleukin-6